These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21131918)

  • 1. Calculator for ovarian carcinoma subtype prediction.
    Kalloger SE; Köbel M; Leung S; Mehl E; Gao D; Marcon KM; Chow C; Clarke BA; Huntsman DG; Gilks CB
    Mod Pathol; 2011 Apr; 24(4):512-21. PubMed ID: 21131918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.
    Altman AD; Nelson GS; Ghatage P; McIntyre JB; Capper D; Chu P; Nation JG; Karnezis AN; Han G; Kalloger SE; Köbel M
    Mod Pathol; 2013 Sep; 26(9):1255-63. PubMed ID: 23558569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.
    Köbel M; Kalloger SE; Lee S; Duggan MA; Kelemen LE; Prentice L; Kalli KR; Fridley BL; Visscher DW; Keeney GL; Vierkant RA; Cunningham JM; Chow C; Ness RB; Moysich K; Edwards R; Modugno F; Bunker C; Wozniak EL; Benjamin E; Gayther SA; Gentry-Maharaj A; Menon U; Gilks CB; Huntsman DG; Ramus SJ; Goode EL;
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1677-86. PubMed ID: 23880734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
    Köbel M; Kalloger SE; Boyd N; McKinney S; Mehl E; Palmer C; Leung S; Bowen NJ; Ionescu DN; Rajput A; Prentice LM; Miller D; Santos J; Swenerton K; Gilks CB; Huntsman D
    PLoS Med; 2008 Dec; 5(12):e232. PubMed ID: 19053170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.
    Köbel M; Rahimi K; Rambau PF; Naugler C; Le Page C; Meunier L; de Ladurantaye M; Lee S; Leung S; Goode EL; Ramus SJ; Carlson JW; Li X; Ewanowich CA; Kelemen LE; Vanderhyden B; Provencher D; Huntsman D; Lee CH; Gilks CB; Mes Masson AM
    Int J Gynecol Pathol; 2016 Sep; 35(5):430-41. PubMed ID: 26974996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
    Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
    Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions.
    Köbel M; Luo L; Grevers X; Lee S; Brooks-Wilson A; Gilks CB; Le ND; Cook LS
    Int J Gynecol Pathol; 2019 Jul; 38(4):353-362. PubMed ID: 29901523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
    Gilks CB; Ionescu DN; Kalloger SE; Köbel M; Irving J; Clarke B; Santos J; Le N; Moravan V; Swenerton K;
    Hum Pathol; 2008 Aug; 39(8):1239-51. PubMed ID: 18602670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histotype classification of ovarian carcinoma: A comparison of approaches.
    Peres LC; Cushing-Haugen KL; Anglesio M; Wicklund K; Bentley R; Berchuck A; Kelemen LE; Nazeran TM; Gilks CB; Harris HR; Huntsman DG; Schildkraut JM; Rossing MA; Köbel M; Doherty JA
    Gynecol Oncol; 2018 Oct; 151(1):53-60. PubMed ID: 30121132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accurate Distinction of Ovarian Clear Cell From Endometrioid Carcinoma Requires Integration of Phenotype, Immunohistochemical Predictions, and Genotype: Implications for Lynch Syndrome Screening.
    Rodriguez M; Kang EY; Farrington K; Cook LS; Le ND; Karnezis AN; Lee CH; Nelson GS; Terzic T; Lee S; Köbel M
    Am J Surg Pathol; 2021 Nov; 45(11):1452-1463. PubMed ID: 34534137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Nestin and CD133 in serous ovarian carcinoma.
    Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
    J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical Profiling of Endometrial Serous Carcinoma.
    Chen W; Husain A; Nelson GS; Rambau PF; Liu S; Lee CH; Lee S; Duggan MA; Köbel M
    Int J Gynecol Pathol; 2017 Mar; 36(2):128-139. PubMed ID: 27167671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Sehouli J; Kunze CA; Dietel M; Braicu I; Letsch A; Darb-Esfahani S
    Gynecol Oncol; 2016 Mar; 140(3):494-502. PubMed ID: 26721227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
    Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
    Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
    Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.